U.S. Drug Shortages

CAPT Valerie Jensen
U.S. Public Health Service
Associate Director, CDER Drug Shortage Program
Center for Drug Evaluation & Research
U.S. Food & Drug Administration
Overview

U.S. Drug Shortage Trends
Reasons for Drug Shortages
FDA’s Role
View of the Future
Drug Shortage Program

Our mission is to prevent, mitigate and help resolve shortages

- Center for Drug Evaluation & Research
  - Drug Shortage Program (DSP) began in 1999
  - Today have 11 full time staff
- Facilitate prevention and resolution of shortages
- Bring together FDA experts, industry, and external stakeholders
- Inform the public
- Outreach to healthcare professional organizations, patient groups and other stakeholders

Who works on this?

Office of New Drugs
Office of New Drug Quality Assessment
Office of Generic Drugs
Office of Compliance
Field Inspectors
MANY OTHERS!
Growing problem – and FDA response

- Current shortage information - website updated daily
- Resources – staff expanded and high level oversight
- Encourage reporting
  - From general public about existing shortages
  - From industry about potential shortages
  - Expand application of authority to require early notifications (Interim Final Rule, Dec. 19, 2011).
  - New FDASIA legislation
- Public workshop September, 2011
- Collaboration on system fixes and root problem resolution
  - American Society of Healthcare Pharmacists (ASHP)
  - Industry (GPHA, PhRMA, BIO)
A Drug Supply Chain Example
From Supplier to Patient
FDA Authorities are very limited

What we can require
• Notification by manufacturers (new FDASIA requirement)
  – Supply disruptions, delays, discontinuations
  – No penalty for not reporting
• Notification of manufacturing changes

What we can’t require
• A company to make a drug or make more
• How much and to whom drug is sold or distributed

FDA Drug Shortages Program largely depends on notification by manufacturers and the public.
Most shortages do get resolved.
Drug shortages 2011: Dosage Forms

Drug Dosage Form of 2011 Shortages

- Dermal/Transdermal: 73%
- Inhalation: 18%
- Injectable: 3%
- Oral Suspension Solution: 1%
- Tablet/Capsule: 1%
- Suppository: 1%
- Other: 2%
2011 Shortage Data

• There were 251 shortages reported in 2011
• High percentage are sterile injectable products
  – Treatments for cancer, anesthesia, serious illness
  – Highly specialized manufacturing
  – High risk to patient if not meticulous

When there are quality or production problem for a sterile injectable drug, a shortage is almost always results
Reasons for Drug Shortages in 2011: All Dosage Forms

- Component Problems: 47%
- Delays/Capacity Issues: 19%
- Discontinuation: 12%
- Increased Demand: 6%
- Loss of Manufacturing Site: 2%
- Other/Unknown: 10%
- Quality Issue: 4%
- Raw Materials (API): 0%
Reasons for Sterile Injectable Shortages in 2011

- Component Problems: 56%
- Delays/Capacity Issues: 9%
- Discontinuation: 7%
- Increased Demand: 4%
- Loss of Manufacturing Site: 2%
- Other/Unknown: 1%
- Quality Issues: 1%
- Raw Materials (API): 1%
Reasons for Shortages: Sterile Injectables

Report by Assistant Secretary for Planning & Evaluation 2011

• State of the industry
  – Seven (7) manufacturers make up most of market
  – Contract manufacturers – firms contract out manufacturing as well as acting as contract manufacturers

• Lack of redundancy
  – Multiple products made on existing manufacturing lines
  – 24/7 production with no “cushion”

• Complex manufacturing process
  – No simple fixes
  – Problems typically affect multiple products

• Investment economics question
  – e.g., propofol 20ml sells for $0.48/vial
Quality and Manufacturing Examples

• Sterility
  – bacterial and mold contamination

• Particles of foreign matter
  – glass, metal and fibers in vials

• Crystallization of the active ingredient

• Precipitate formation
  – due to reaction with raw materials or container/stopper with the drug

• New impurities or degradants

• Equipment breakdown
  – Plant maintenance

• Natural disasters
How does FDA fit?

• Patient care is our #1 concern
• We get involved when we are informed
  – Early notification is critical
• Seek ways to prevent & mitigate shortages
  – Secondary response to industry problem
  – Find root cause and get manufacturer on track
• Some shortages can be prevented, but not all
  – Unforeseen breakdown in manufacturing system
  – Longstanding quality manufacturing problems
• Some can be addressed quickly, others not
  – Risks to the patient always considered
FDA’s Approach to Prevention/Mitigation

- Prioritize products that are medically necessary
- Risk/Benefit of the drug always considered
- Do everything possible to continue availability while minimizing risk to patients.
- Work with firm to address
  - We can advise, assist and expedite, but only the manufacturer can fix the problem
  - Why we encourage early notification so we are aware of problems quickly
- Be flexible and creative – and fast
Medical Necessity

• A medically necessary drug product is a product that is used to treat or prevent a serious disease or medical condition for which there is no other alternative drug, available in adequate supply, that is judged by medical staff to be an adequate substitute.

CDER Manual of Policies and Procedures on Drug Shortage Management 6003.1
FDA Tool Box

- Regulatory discretion: allow manufacture of medically necessary product(s) to continue
  - Minor, low risk issues usually best suited for this tool
  - In some cases require additional safety controls
  - Filters packaged with product; extra testing at plant; 3rd party oversight of production; special instructions for safe use
- Request other firms to ramp up manufacturing.
- Expedite any review of company proposals
  - New manufacture site, increased expiry, new raw material source, changes in specifications, etc.
- In rare cases, temporary importation from unapproved sources
  - 2010 propofol
  - 2011 foscarnet, ethiodol, thiotepa, norepinephrine, Xeloda, levoleucovorin, leucovorin
  - 2012 methotrexate, doxorubicin liposomal, propofol, phentolamine
38 Shortages Prevented in 2010

- All due to firms notifying FDA of problems early
- 16 through regulatory discretion
  - Risk of quality/manufacturing issue able to be mitigated and was outweighed by benefit of the drug
- 13 through expedited review
  - New manufacturing sites, suppliers, etc.
- 8 through encouraging other firms to ramp up
- 1 through communication with DEA regarding firm’s need for controlled substance quota increase
195 Shortages Prevented in 2011

- Most due to firms notifying the FDA of early problems
- The main FDA action taken to prevent drug shortage was Expedited Review
- Other actions taken include:
  - Regulatory discretion
  - Ramping up production
  - Assistance with release
  - Extension of expiry of available products
  - Additional testing
Reporting

Drug Shortage Notification Source 2011

- FDA: 32
- Manufacturer: 57
- Public: Healthcare professional: 4
- Public: Professional organization: 157
- Report through FDA website: 1
President’s Executive Order issued 10/31/11 encouraged more voluntary reporting by manufacturers

- 6 fold increase in notifications of potential shortages
  - Usual 10 per month (2010) rose to 60 per month!
- Total of 195 shortages prevented in 2011
- 98 shortages prevented as of August, 2012
Shortages can not always be prevented

- Unanticipated events occur
  - manufacturing line breakdown or natural disaster
- Sometimes manufacturers can’t make up production shortfall
- If systemic, plant may have to close to repair
- FDA works with company to encourage smart distribution
  - No easy answers on how to do this well
Anatomy of Methotrexate

Bedford Labs/ Ben Venue
2ml, 4 ml, 8 ml & 10 ml vials

Mylan
2 ml & 40 ml vials

APP
10 ml vials

Pediatric leukemia

Sandoz
2ml vials RECALL
10 ml vials DELAY
40 ml vials DELAY

Hospira
2ml & 40 ml vials
Methotrexate Injection

- Bedford/Ben Venue biggest supplier
  - Working with the firm to resume select production
- Other 4 firms stretched to fill gap
  - Expedited review of applications relating to increasing production
- Used regulatory discretion for additional supply to be imported to help meet patient needs
“Gray Market”

• Sources that have extra product (may collect it) and sell at higher than market prices
  – Close link to “local stockpiling” with blurred margins
• Not clear what, if any laws are being broken
• Extent unknown, but many complaints
• FDA reports these to the Department of Justice for investigation
• Raises FDA concern about potential for counterfeit drugs filling gaps
The Future

• FDA Drug Shortage work will continue
  – Multidisciplinary: clinicians, pharmacists, chemists, biotechnology, regulatory and manufacturing
  – We can only prevent shortages if problems are reported
  – Public communication of existing shortages

• New FDASIA legislation
  – REQUIRES broader reporting by industry to FDA

• Must have industry commitment to culture of quality manufacturing
  – Many firms are building new plants today
  – Need better methods and redundancy
  – Promptly report and correct even small problems
Thank You

• FDA drug shortage website is:

• To report shortages our e-mail account is
  Drugshortages@fda.hhs.gov

• FDA Webinar on Prescription Drug Shortages
  Sept. 30, 2011,
  http://www.fda.gov/AboutFDA/Transparency/Basics/
  ucm272223.htm